Recent advances in the treatment of triple-negative breast cancer

Triple-negative is the rarest breast cancer biological subtype of cancer, but has most aggressive course. The resuls chemotherapy, especially in advanced disease, are unsatisfactory. Numerous clinical trials have been conducted, that resulted registrations new drugs decreasing risk recurrence and improving outcome patients with metastatic disease. article summarizes data on modern therapies registered recent years. role pembrolizumab perioperative treatment early stage was indicated, as well importance olaparib BRCA mutation carriers. Additionally, indication for immunotherapy (pembrolizumab atezolizumab), sacituzumab govitecan PARP inhibitors (olaparib talazoparib) carriers were highlighted.